Biotech News
Related news
BNTXBioNTech2026-10-13 10:45 EST
BioNTech veröffentlicht Update zur klinischen Phase-2/3-Studie des mRNA-Krebsimmuntherapiekandidaten BNT113 bei HPV16-positivem metastasiertem Kopf- und Halskrebs
RVMDRevolution Medicines2026-10-20 12:00 EST
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
LYELLyell Immunopharma2026-09-10 20:05 EST
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
RVMDRevolution Medicines2026-10-15 13:46 EST
Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
GPCRStructure Therapeutics2026-09-08 12:00 EST
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
IMCRImmunocore Holdings plc2026-10-15 11:00 EST
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
TEVATeva Pharmaceutical Industries2026-09-02 11:03 EST
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
ARGXArgenx2026-10-08 05:00 EST
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
GSKGSK plc2026-09-13 19:30 EST
GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer
BioNTech
Next-Generation Biopharmaceutical Platform BioNTech develops medicines for cancer and other serious diseases using complementary immunotherapy and vaccine technologies. Its current oncology strategy integrates checkpoint and angiogenesis modulation, antibody-drug conjugates and mRNA cancer immunotherapies across multiple tumor...
Recent company news
BNTXBioNTech2026-10-20 10:45 EST
BioNTech veröffentlicht am 3. November 2026 Ergebnisse für das dritte Quartal 2026 und informiert über operativen Fortschritt
BNTXBioNTech2026-10-20 10:45 EST
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
BNTXBioNTech2026-10-19 10:45 EST
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
BNTXBioNTech2026-10-13 10:45 EST
BioNTech veröffentlicht Update zur klinischen Phase-2/3-Studie des mRNA-Krebsimmuntherapiekandidaten BNT113 bei HPV16-positivem metastasiertem Kopf- und Halskrebs
BNTXBioNTech2026-10-13 10:45 EST
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
Stock data
- Close
- 91.17 USD
- Market cap
- 22.54B USD
- Exchange
- NASDAQ
- Sector
- Nucleic Acid Drugs
- Location
- United States